Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells

Taiwanese Journal of Obstetrics and Gynecology

Volumn 50, Issue 2, 2011, Pages 165-171

  Ma, Yen Ying ^a,b   Lin, Hao ^a,b   Moh, Jau Sung ^c   Chen, Kuang Den ^a   Wang, I Wen ^a   Ou, Yu Che ^a,b   You, Ying Shu ^d   Lung, Chia Chi ^d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c FORTUNE INSTITUTE OF TECHNOLOGY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cisplatin; Drug resistance; LBH589; Ovarian cancer; Sensitivity

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON RECEPTOR 2; CASPASE 8; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; EXCITATORY AMINO ACID TRANSPORTER 3; FRASER SYNDROME 1 PROTEIN; GAP JUNCTION PROTEIN EPSILON 1; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A2; GLUTATHIONE TRANSFERASE A5; HLA DMA ANTIGEN; HLA DMB ANTIGEN; HLA DPA ANTIGEN; HLA DRB5 ANTIGEN; HYDROLASE; KALLIKREIN RELATED PEPTIDASE 10; KALLIKREIN RELATED PEPTIDASE 8; MESSENGER RNA; METHIONINE ADENOSYLTRANSFERASE 1ALPHA; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 2; NUCLEOTIDE; PANOBINOSTAT; PROTEIN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; SLC17A5 PROTEIN; SLC40A1 PROTEIN; STONIN 1; SULFATASE 2; TELOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IMMUNE RESPONSE; ION TRANSPORT; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; RECEPTOR BINDING; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; MICROARRAY ANALYSIS; OVARIAN NEOPLASMS; RNA;

EID: 79960635636     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2011.01.022     Document Type: Article

References (34)

1. Lin H., Changchien C.C. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches. Taiwan J Obstet Gynecol 2007, 46:379-388.
2. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3:502-516.
3. Isonishi S., Andrews P.A., Howell S.B. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem 1990, 265:3623-3627.
4. Isonishi S., Ohkawa K., Tanaka T., Howell S.B. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. Br J Cancer 2000, 82:34-38.
5. Lin C.T., Lai H.C., Lee H.Y., Lin W.H., Chang C.C., Chu T.Y., et al. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 2008, 99:1218-1226.
6. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000, 60:6039-6044.
7. Bardella C., Dettori D., Olivero M., Coltella N., Mazzone M., Di Renzo M.F. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res 2007, 13:2191-2198.
8. Kikuchi Y., Hirata J., Kita T., Imaizumi E., Tode T., Nagata I. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in human ovarian cancer cells. Gynecol Oncol 1993, 49:365-372.
9. Goyeneche A.A., Caron R.W., Telleria C.M. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007, 13:3370-3379.
10. Ferrandina G., Lauriola L., Zannoni G.F., Fagotti A., Fanfani F., Legge F., et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002, 13:1205-1211.
11. Glasspool R.M., Teodoridis J.M., Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006, 94:1087-1092.
12. Liu F.S. Mechanisms of chemotherapeutic drug resistance in cancer therapy-a quick review. Taiwan J Obstet Gynecol 2009, 48:239-244.
13. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
14. Lund A.H., van Lohuizen M. Epigenetics and cancer. Genes Dev 2004, 18:2315-2335.
15. Witt O., Deubzer H.E., Lodrini M., Milde T., Oehme I. Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 2009, 15:436-447.
16. Emanuele S., Lauricella M., Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol 2008, 33:637-646.
17. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007, 74:659-671.
18. Beckers T., Burkhardt C., Wieland H., Gimmnich P., Ciossek T., Maier T., et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007, 121:1138-1148.
19. Rasheed W.K., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007, 16:659-678.
20. Ellis L., Pan Y., Smyth G.K., George D.J., McCormack C., Williams-Truax R., et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008, 14:4500-4510.
21. Verheul H.M., Salumbides B., Van Erp K., Hammers H., Qian D.Z., Sanni T., et al. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 2008, 14:3589-3597.
22. Yu C., Friday B.B., Yang L., Atadja P., Wigle D., Sarkaria J., et al. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro Oncol 2008, 10:309-319.
23. Steele N., Finn P., Brown R., Plumb J.A. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 2009, 100:758-763.
24. Harries M., Kaye S.B. Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs 2001, 10:1715-1724.
25. Prystowsky M.B., Adomako A., Smith R.V., Kawachi N., McKimpson W., Atadja P., et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol 2009, 218:467-477.
26. Edwards A., Li J., Atadja P., Bhalla K., Haura E.B. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007, 6:2515-2524.
27. Qian D.Z., Kato Y., Shabbeer S., Wei Y., Verheul H.M.W., Salumbides B., et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006, 12:634-642.
28. Scuto A., Kirschbaum M., Kowolik C., Kretzner L., Juhasz A., Atadja P., et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008, 111:5093-5100.
29. Fazzone W., Wilson P.M., Labonte M.J., Lenz H.J., Ladner R.D. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer 2009, 125:463-473.
30. Walton T.J., Li G., Seth R., McArdle S.E., Bishop M.C., Rees R.C. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 2008, 68:210-222.
31. Maiso P., Carvajal-Vergara X., Ocio E.M., López-Pérez R., Mateo G., Gutiérrez N., et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66:5781-5789.
32. Rosato R.R., Almenara J.A., Yu C., Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004, 65:571-581.
33. Ellis L., Bots M., Lindemann R.K., Bolden J.E., Newbold A., Cluse L.A. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009, 114:380-393.
34. Fiskus W., Pranpat M., Bali P., Balasis M., Kumaraswamy S., Boyapalle S., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006, 108:645-652.